Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

3.310 -0.250 (-7.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,051,738
Open 3.590
Bid (Size) 3.310 (4)
Ask (Size) 3.340 (4)
Prev. Close 3.560
Today's Range 3.230 - 3.680
52wk Range 2.780 - 8.580
Shares Outstanding 67,578,549
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
It's facing a few issues that are practically guaranteed to affect shareholder returns. 
Via The Motley Fool
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering. 
Via Benzinga

Performance

YTD
-52.31%
-52.31%
1 Month
-24.26%
-24.26%
3 Month
-36.71%
-36.71%
6 Month
-55.09%
-55.09%
1 Year
+3.44%
+3.44%

More News

Read More
Why Is Bluebird Bio (BLUE) Stock Up 17% Today?
Via InvestorPlace
bluebird bio Inc. (NASDAQ: BLUE) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
Should Investors Buy the Dip With Bluebird Bio Stock?
Via The Motley Fool
bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
1 Incredibly Undervalued Growth Stock to Buy Hand Over Fist in May
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2023
Via Benzinga
1 Small-Cap Stock That Could Soar in 2023
Via The Motley Fool
Why First Republic Bank Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Intel, Saia, Charter Communications And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Bluebird Bio Stock Is Sinking This Week
Via The Motley Fool
bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events
From bluebird bio
Via Business Wire
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023
Via Benzinga
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
Via Benzinga
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis
Via Benzinga
Nasdaq Surges 100 Points; US Producer Prices Drop In March
Via Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio
Via The Motley Fool
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.